<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>An Epstein-Barr virus (EBV)-negative lymphoblastoid cell line (LCL), BJA-B, was established from an African Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) which contained no detectable EBV DNA and did not express the EBV specified antigen EBNA, BJA-B cells grow in typically large, flat clumps </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> carry surface-bound immunoglobulins, a B lymphocyte marker, and do not form rosettes with sheep erythrocytes </plain></SENT>
<SENT sid="2" pm="."><plain>After <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> of BJA-B cells by EBV the infected cells may produce either EBV-determined nuclear antigen (EBNA) or both EBNA and early antigen (EA), depending on the strain of EBV </plain></SENT>
<SENT sid="3" pm="."><plain>The homogeneity of the BJA-B cell population with respect to immunological and isoenzyme markers and size suggests a clonal origin of the line </plain></SENT>
<SENT sid="4" pm="."><plain>BJA-B is the first EBV-negative LCL established from an African Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and demonstrates that an EBV-independent continuous B cell line can be established "in vitro" from other than <z:hpo ids='HP_0001909'>leukemia</z:hpo> or <z:mp ids='MP_0009440'>myeloma</z:mp> cells </plain></SENT>
</text></document>